About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy

By: via GlobeNewswire

SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation® therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona.

WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation® therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evaluate and compare the safety and efficacy of Aquablation therapy and radical prostatectomy for men with Grade Group 1 to 3 localized prostate cancer. Aquablation therapy is an image-guided, minimally invasive surgery that aims to resect (remove) diagnosed cancer and most of the prostate using a robotically-controlled waterjet. Radical prostatectomy is a traditional surgery that removes the entire prostate along with some surrounding tissue. A surgical robot is often used to perform the radical prostatectomy surgery.

“While most WATER IV PCa trial sites will treat patients in a hospital setting, Dr. Mehan has elected to treat his randomized Aquablation therapy trial patients at an ASC,” said Barry Templin, chief technology officer of PROCEPT BioRobotics. “This announcement marks a major milestone: we have demonstrated early-stage prostate cancer can be safely treated at an ASC with Aquablation therapy. With a prostate cancer treatment approach that removes significantly more tissue than a typical BPH procedure or focal therapy, Dr. Mehan successfully completed all procedures and discharged patients the same day without complications. This is indicative of not only a safe prostate resection, but also the potential for a more scalable, cost-effective care model in a rapidly changing market.”

“WATER IV PCa, a unique and thoughtful randomized trial design focusing on harm reduction by using Aquablation therapy as first line treatment in comparison to radical prostatectomy for men with Grade Group 1 to 3 localized prostate cancer, could potentially change the way urologists treat localized prostate cancer for millions of men,” said, Inderbir Gill, MD, Global co-PI of the WATER IV trial and founding executive director of USC Institute of Urology, part of Keck Medicine of USC and chairman, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine of USC. “It is exciting to see that the FDA approved this IDE after a prompt and thorough review of the trial design, and we look forward to seeing the results of our forthcoming trial and are hopeful about the possibilities of this novel treatment approach for the most commonly diagnosed internal cancer in men.”

About Aquablation Therapy
Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of benign prostatic hyperplasia (BPH). The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements.

Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com


Primary Logo

More News

View More
JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall?
Via MarketBeat
Topics Earnings
Tickers BAC JPM KBWB
Snap-on Incorporated: Snap It Up Quick, New Highs Will Come Soon
Via MarketBeat
Tickers SNA
As Global Renewables Surpass Coal, This ETF Offers Smart Exposure
Via MarketBeat
Topics ETFs Energy
Tickers BE FSLR ICLN
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Via MarketBeat
Tickers JNJ KVUE PTGX
Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
Via MarketBeat
Topics Artificial Intelligence
Tickers TSLA

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.